Hansa’s first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, in patients with severe Crigler-Najjar syndrome and pre-formed antibodies to AAV serotype 8 (AAV8). Søren ...

responses to the tetanus vaccine was similar in both groups—39.1% of rituximab-treated patients had a 4-fold or greater increase in anti-tetanus immunoglobulin G titers from baseline compared ...

Genethon & Hansa begin phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome: Lund, Sweden Wednesday, December 4, 2024, 18:00 Hrs [IST] Hans ...

IVIg is administered in a standard dose of 2 g/kg divided over 3-5 days; however, despite this therapy, some patients ... treated with 2 g/kg of IVIg. Total IgG levels were determined in serum ...

This is a crucial step in order to make gene therapy more effective and to increase the number of patients able to access it.

This article reviews IVIG therapy, its uses, how it works, and what to expect when receiving it. Immunoglobulins are also ...